OBJECTIVE: Infantile spasm syndrome (ISS) is an epileptic encephalopathy without established treatment after the failure to standard of care based on steroids and vigabatrin. Converging lines of evidence indicating a role of NR2B subunits of the N-methyl-D-aspartate (NMDA) receptor on the onset of spams in ISS patients, prompted us to test radiprodil, a negative allosteric NR2B modulator in preclinical seizure models and in infants with ISS. METHODS: Radiprodil has been tested in three models, including pentylenetetrazole-induced seizures in rats across different postnatal (PN) ages. Three infants with ISS have been included in a phase 1b escalating repeated dose study. RESULTS: Radiprodil showed the largest protective seizure effects in juvenile rats (maximum at PN12, corresponding to late infancy in humans). Three infants resistant to a combination of vigabatrin and prednisolone received individually titrated doses of radiprodil for up to 34 days. Radiprodil was safe and well tolerated in all three infants, and showed the expected pharmacokinetic profile. One infant became spasm-free and two showed clinical improvement without reaching spasm-freedom. After radiprodil withdrawal, the one infant continued to be spasm-free, while the two others experienced seizure worsening requiring the use of the ketogenic diet and other antiepileptic drugs. INTERPRETATION: Radiprodil showed prominent anti-seizure effect in juvenile animals, consistent with the prevalent expression of NR2B subunit of the NMDA receptor at this age in both rodents and humans. The clinical testing, although preliminary, showed that radiprodil is associated with a good safety and pharmacokinetic profile, and with the potential to control epileptic spasms.

Institute of Physiology The Czech Academy of Sciences Prague Czech Republic

Service de Neurologie Pédiatrique Hôpital Robert Debré Paris France

UCB Pharma Braine L'Alleud Belgium

Université de Paris INSERM U1141 F 75019 Paris France

Zobrazit více v PubMed

Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the west Delphi group. Epilepsia 2004;45:1416–1428. PubMed

Hrachovy RA, Frost JD, Kellaway P. Hypsarrhythmia ‐ variations on the theme. Epilepsia 1984;25:317–325. PubMed

McTague A, Howell KB, Cross JH, et al. The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol 2016;15:304–316. PubMed

Muir A, Myers C, Nguyen N, et al. Genetic heterogeneity in infantile spasms. Epilepsy Res 2019;156:106181. PubMed PMC

Osborne JP, Lux AL, Edwards SW, et al. The underlying etiology of infantile spasms (West syndrome): information from the United Kingdom Infantile Spasms Study (UKISS) on contemporary causes and their classification. Epilepsia 2010;51:2168–2174. PubMed

Lagae L, Verhelst H, Ceulemans B, et al. Treatment and long term outcome in West syndrome: the clinical reality. A multicentre follow up study. Seizure‐European. J Epilepsy 2010;19:159–164. PubMed

Osborne JP, Edwards SW, Alber FD, et al. The underlying etiology of infantile spasms (West syndrome): information from the International Collaborative Infantile Spasms Study (ICISS). Epilepsia 2019;60:1861–1869. PubMed

Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 2013;14:383–400. PubMed

Ghasemi M, Schachter SC. The NMDA receptor complex as a therapeutic target in epilepsy: a review. Epilepsy Behav 2011;22:617–640. PubMed

Cowan LD, Hudson LS. The epidemiology and natural‐history of infantile spasms. J Child Neurol 1991;6:355–364. PubMed

Wilmshurst JM, Gaillard WD, Vinayan KP, et al. Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics. Epilepsia 2015;56:1185–1197. PubMed

O'Callaghan FJK, Lux AL, Darke K, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia 2011;52:1359–1364. PubMed

Auvin S, Hartman A, Desnous B, et al. Diagnosis Delay in West syndrome: misdiagnosis and consequences. Eur J Pediatr 2012;171:1695–1701. PubMed

O'Callaghan FJK, Edwards SW, Alber FD, et al. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18‐month outcomes of an open‐label, randomised controlled trial. Lancet Child Adolesc Health 2018;2:715–725. PubMed

O'Callaghan FK, Edwards SW, Alber FD, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open‐label trial. Lancet Neurol 2017;16:33–42. PubMed

Baram TZ, Mitchell WG, Tournay A, et al. High‐dose corticotropin (ACTH) versus prednisone for infantile spasms: A prospective, randomized, blinded study. Pediatrics 1996;97:375–379. PubMed PMC

Rho JA. Basic science behind the catastrophic epilepsies. Epilepsia 2004;45(s5):5–11. PubMed

Pierson T, Yuan H, Marsh E, et al. GRIN2A mutation and early‐onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol 2014;1:190–198. PubMed PMC

Chachua T, Yum M‐S, Veliskova J, Velisek L. Validation of the rat model of cryptogenic infantile spasms. Epilepsia 2011;52:1666–1677. PubMed PMC

Velisek L, Chachua T, Yum M‐S, et al. Model of cryptogenic infantile spasms after prenatal corticosteroid priming. Epilepsia 2010;51:145–149. PubMed PMC

Rakhade SN, Jensen FE. Epileptogenesis in the immature brain: emerging mechanisms. Nat Rev Neurol 2009;5:380–391. PubMed PMC

Mares P, Mikulecka A. Different effects of two N‐methyl‐D‐aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats. Epilepsy Behav 2009;14:32–39. PubMed

Mares P. Age and activation determines the anticonvulsant effect of ifenprodil in rats. N‐S Arch Pharmacol 2014;387:753–761. PubMed

Lemke JR, Geider K, Helbig KL, et al. Delineating the GRIN1 phenotypic spectrum: a distinct genetic NMDA receptor encephalopathy. Neurology 2016;86:2171–2178. PubMed PMC

Platzer K, Yuan H, Schuetz H, et al. GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects. J Med Genet 2017;54:460–470. PubMed PMC

Mullier B, Wolff C, Sands ZA, et al. GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B‐containing NMDA receptors. Neuropharmacology 2017;123:322–331. PubMed

Sciberras D, Otoul C, Lurquin F, et al. A pharmacokinetic study of radiprodil oral suspension in healthy adults comparing conventional venous blood sampling with two microsampling techniques. Pharmacol Res Perspect 2019;7:e00459. PubMed PMC

Mares P. Models of epileptic seizures in immature rats. Physiol Res 2012;61:S103–S108. PubMed

Dozières‐Puyravel B, Nasser H, Bellavoine V, et al. Felbamate for infantile spasms syndrome resistant to first‐line treatments. Dev Med Child Neurol 2019;DOI:10.1111/dmcn.14427 PubMed DOI

Babb TL, Mikuni N, Najm I, et al. Pre‐ and postnatal expressions of NMDA receptors 1 and 2B subunit proteins in the normal rat cortex. Epilepsy Res 2005;64:23–30. PubMed

Wenzel A, Fritschy JM, Mohler H, Benke D. NMDA receptor heterogeneity during postnatal development of the rat brain: Differential expression of the NR2A, NR2B, and NR2C subunit proteins. J Neurochem 1997;68:469–478. PubMed

Monyer H, Burnashev N, Laurie DJ, et al. Developmental and regional expression in the rat‐brain and functional‐properties of 4 NMDA receptors. Neuron 1994;12:529–540. PubMed

Riikonen R. Update to guidelines on treatment of infantile spasms. Nat Rev Neurol 2012;8:480–482. PubMed

Rho JM, Donevan SD, Rogawski MA. Mechanism Of action of the anticonvulsant felbamate ‐ opposing effects on N‐methyl‐D‐aspartate and gamma‐aminobutyric‐acid, receptors. Ann Neurol 1994;35:229–234. PubMed

Pellock JM, Faught E, Leppik IE, et al. Felbamate: consensus of current clinical experience. Epilepsy Res 2006;71:89–101. PubMed

Hurst DL, Rolan TD. The use of felbamate to treat infantile spasms. J Child Neurol 1995;10:134–136. PubMed

Hosain S, Nagarajan L, Carson D, et al. Felbamate for refractory infantile spasms. J Child Neurol 1997;12:466–468. PubMed